Results 51 to 60 of about 590 (119)

Do randomized clinical trials always provide certain results? The case of tralokinumab in idiopathic pulmonary fibrosis

, 2018
Do Randomized Clinical Trials Always Provide Certain Results?
Jones, Mark G., Luca Richeldi, Mark G. Jones, Giacomo Sgalla, Sgalla, Giacomo, Richeldi, Luca   +5 more
core   +1 more source

Anchored Matching-Adjusted Indirect Comparison of the Long-Term Maintenance of Efficacy of Tralokinumab and Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis

Dermatology and Therapy
Introduction Atopic dermatitis (AD) is a chronic skin disease largely driven by interleukin (IL)-13, which is targeted by tralokinumab and lebrikizumab.
Matthias Augustin, April Armstrong, Naiem T. Issa, Anne Sohrt Petersen, Rie von Eyben, Teodora Festini, Tiago Torres   +6 more
doaj   +1 more source

Eosinophilia Reflects Type 2 Immune Activation in Newly Diagnosed Bullous Pemphigoid, With No Evidence of Charcot‐Leyden Crystals

Allergy, EarlyView.
Janik Fleißner, Tassilo Dege, Sandrine Benoit, Matthias Goebeler, Andreas Kerstan   +4 more
wiley   +1 more source

Bullous Pemphigoid Disease Area Index Pruritus, Activity, and Damage During Biologic Therapy in Bullous Pemphigoid: An International Dual‐Center Study

The Journal of Dermatology, Volume 53, Issue 9, Page 1353-1357, September 2026.
ABSTRACT Biologic therapies targeting Type 2 inflammation are increasingly used in bullous pemphigoid, yet the relationship between pruritus and distinct disease domains remains incompletely defined. We conducted a retrospective international dual‐center study of 25 patients with bullous pemphigoid treated with dupilumab, omalizumab, or tralokinumab ...
Ruggero Cascio Ingurgio, Angela Alfano, Aalia Syed, Luigi Gargiulo, Alessandra Narcisi, Antonio Costanzo, Dedee F. Murrell   +6 more
wiley   +1 more source

Targeting interleukin-13 with tralokinumab reduces S. aureus abundance in adolescents with atopic dermatitis

, 2023
International audiencePatients with atopic dermatitis (AD) are frequently colonized with high levels of S.aureus. Dysregulation of the skin microbiome in AD is influenced by epidermal barrier disruption and type 2 inflammation.
Tauber, Marie, Beck, Lisa A., Kurbasic, Azra, Werfel, Thomas, Arlert, Petra, Irvine, Alan, Paller, Amy, Saeki, Hidehisa, Eichenfield, Lawrence, Røpke, Mads, Weidinger, Stephan   +10 more
core   +1 more source

Real-World Clinical Experience of Tralokinumab in a Tertiary Centre: An Alternative for Patients with Conjunctivitis on Dupilumab?

Dermatology and Therapy
Introduction Tralokinumab, a human IgG4 monoclonal antibody that inhibits the IL-13 pathway, is approved for the treatment of atopic dermatitis. However, real-world data are lacking and are needed to inform its efficacy and safety in broader populations.
Neenu Sebastian, Omar Chircop, Tim H. Clayton, Firas C. Kreeshan, Hamish J. A. Hunter, Richard B. Warren   +5 more
doaj   +1 more source

Real-life Case-series Experience with Tralokinumab in Patients with Severe Atopic Dermatitis: When to Consider Tralokinumab?

Journal of Dermatology and Dermatologic Surgery
Atopic dermatitis (AD) is a chronic inflammatory skin condition driven largely by type-2 immune responses, particularly interleukin-13 (IL-13). Tralokinumab, a monoclonal antibody targeting IL-13, has emerged as a novel biologic therapy for moderate-to ...
Fares A. Alkhayal, Ahmed F. Alanazi, Kadi S. Alsubaie   +2 more
doaj   +1 more source

The Intriguing Role of Interleukin 13 in the Pathophysiology of Asthma

Frontiers in Pharmacology, 2019
Approximately 5–10% of asthmatic patients worldwide suffer from severe asthma. Experimental and clinical studies have demonstrated that IL-13 is an important cytokine in chronic airways inflammation.
Giancarlo Marone, Giancarlo Marone, Francescopaolo Granata, Francescopaolo Granata, Valentina Pucino, Antonio Pecoraro, Enrico Heffler, Enrico Heffler, Stefania Loffredo, Stefania Loffredo, Stefania Loffredo, Guy W. Scadding, Gilda Varricchi, Gilda Varricchi, Gilda Varricchi   +14 more
doaj   +1 more source

Effect of Dupilumab on Airway Inflammation in Patients With Persistent Asthma

Allergy, Volume 81, Issue 9, Page 3261-3272, September 2026.
EXPEDITION (NCT02573233) assessed the effects of dupilumab on airway inflammation in patients with persistent asthma using bronchoscopy and gene expression analysis. Dupilumab showed no appreciable effect on inflammatory cell types in biopsies or BALF samples.
Michael E. Wechsler, Sally E. Wenzel, Steve D. Groshong, Mario Castro, Ian D. Pavord, Klaus F. Rabe, Elizabeth Laws, Alexandre Jagerschmidt, Kaitlyn Gayvert, Sivan Harel, Jennifer D. Hamilton, Nikhil Amin, Lu Zhang, Heming Xing, Anissa Elfakir, Bema Coulibaly, Souâd Naimi, Sara Hamon, Paul J. Rowe, Frank Nestle, Danen M. Cunoosamy, Emanuele de Rinaldis, Leda P. Mannent   +22 more
wiley   +1 more source

Patient-oriented measures for phase 3 studies of tralokinumab for treatment of atopic dermatitis (ECZTRA 1, 2 and 3)

, 2022
BACKGROUND: Tralokinumab, as monotherapy or in combination with topical corticosteroids (TCS), has demonstrated significant efficacy through 52 weeks in phase 3 trials of adults with moderate-to-severe atopic dermatitis (AD) and additional efficacy in a ...
Silverberg, Jonathan I, Steffensen, Louise Abildgaard, Zoidis, John, Kurbasic, Azra, Soong, Weily, Schneider, Shannon, Simpson, Eric L, Wollenberg, Andreas, Eric L. Simpson, Weily Soong, John Zoidis, Andreas Wollenberg, Azra Kurbasic, Shannon Schneider, Louise Abildgaard Steffensen, Jonathan I. Silverberg   +15 more
core   +1 more source